Accessibility Menu
Nascent Biotech logo

Nascent Biotech(OTC) NBIO

Market Cap$51.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-100%
5 Year-100%
1 Year-67%
1 Month+50%
$0.00
+0.00%
+0.00Today
Nascent Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-03
Nascent Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-13
1 month+50%USD 0.002026-08-04
3 month-25%USD 0.002026-06-02
Year to date-50%USD 0.002025-12-31
1 year-66.67%USD 0.002025-09-03
3 year-99.47%USD 0.062023-09-01
5 year-99.68%USD 0.092021-09-03
Since inception-99.97%USD 1.012014-08-05

Nascent Biotech Financials at a Glance

Market Cap

$51.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.38

Net Income (TTM)

-$1.35M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-5.65 (Low)

Price

$0.00

Volume

10,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.13

Estimated Earnings Date

Jul 4, 2025

NBIO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nascent Biotech

Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody-based treatments for various cancers. The company is primarily advancing Pritumumab, a therapeutic aimed at aggressive brain malignancies and other epithelial cancers. Additionally, Nascent Biotech is enhancing its proprietary technology platform, MultiPharm, for broader applications in healthcare.

Products and Services
  • Pritumumab for treating aggressive brain cancers
  • MultiPharm technology platform for diverse medical applications
  • Research and development in cancer therapies and autoimmune disorders
Growth Outlook
  • Focus on expanding clinical trials for Pritumumab
  • Potential market for cancer therapies projected to grow significantly
  • Advancements in MultiPharm technology may open new revenue streams
Financial Highlights
  • Recent quarterly net income of -$252,000, reflecting ongoing R&D investments
  • Trailing twelve months (TTM) cash flow from operations shows a negative trend
  • Current ratio of 0.68 indicates potential liquidity challenges
Nascent Biotech, Inc. operates in the biotechnology sector, with a commitment to addressing critical healthcare needs through innovative treatments. The company's flagship product, Pritumumab, is in development to target aggressive brain cancers, which presents a significant market opportunity given the rising incidence of such conditions. The MultiPharm platform further enhances the company's potential by offering a versatile approach to various diseases, including diabetes and autoimmune disorders. Financially, the company has faced challenges, as indicated by recent quarterly losses and a negative cash flow trend. However, the focus on research and development suggests a long-term strategy aimed at establishing a foothold in the competitive biopharmaceutical landscape. The current ratio indicates liquidity concerns, which may require careful management as the company progresses through its clinical trials and seeks to capitalize on its innovative therapies. Overall, Nascent Biotech presents a compelling case for investors interested in the biotechnology sector, particularly those looking for opportunities in cancer treatment advancements.
AI Generated • Aug 27, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Sean Carrick

Website

www.nascentbiotech.com

Headquarters

North Palm Beach, FL 33408, US

NBIO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

268.93%

Return on Capital

N/A

Return on Assets

-378.18%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$51.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

172.84M

Volume

10.00K

Avg. Volume

17.79K

Financials (TTM)

Gross Profit

-$295.63K

Operating Income

-$1.51M

EBITDA

-$1.50M

Operating Cash Flow

-$1.35M

Capital Expenditure

-$2.00

Free Cash Flow

-$1.35M

Cash & ST Invst.

$1.82K

Total Debt

$59.00K

Nascent Biotech Performance Analysis

Nascent Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31USD 1,000,000N/A
20232023-03-31USD 0N/A
20242024-03-31USD 0N/A
Nascent Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-12-31N/A
Q42024-03-31N/A
Q12024-06-30-100.0%
Q22024-09-30N/A
Nascent Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31USD -0.00N/A
20232023-03-31USD -0.02436.4%
20242024-03-31USD -0.01-43.2%
Nascent Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-12-3178.6%
Q42024-03-31-150.0%
Q12024-06-3026.7%
Q22024-09-3031.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$51.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$25.95K

N/A

Employees

2

N/A

Net Income

-$252.00K

+69.6%

EBITDA

-$251.00K

+64.3%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$1.82K

-99.8%

Total Debt

$59.00K

-80.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$59.00K

-80.7%

Return on Assets

-3.78%

N/A

Return on Invested Capital

8.69%

N/A

Free Cash Flow

-$324.73K

-99.6%

Operating Cash Flow

-$324.73K

-99.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
WSNAFWesana Health Holdings Inc.
$0.00+0.00%
RLBDReal Brands, Inc.
$0.00+0.00%
PZOOPazoo, Inc.
$0.00+0.00%
VIVXFAvivagen Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About NBIO

What is the current price of Nascent Biotech?

Nascent Biotech is trading at $0.00 per share.

What is the 52-week range for Nascent Biotech?

Over the past 52 weeks, Nascent Biotech has traded between $0.00 and $0.13.

How much debt does Nascent Biotech have?

As of the most recent reporting period, Nascent Biotech reported total debt of $59.00K.

How much cash does Nascent Biotech have on hand?

Nascent Biotech reported $1.82K in cash and cash equivalents in its most recent financial results.

What is Nascent Biotech’s dividend yield?

Nascent Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services